Article: LC-UV-MS method development for antibody drug conjugates using a non-toxic ADC-mimic
Antibody-drug conjugates (ADC) represent a rapidly emerging class of biotherapeutic molecules, which harness the specificity of monoclonal antibodies (mAb) to selectively deliver highly potent cytotoxic drugs. Like all biotherapeutics they require significant analytical characterization.
A non-toxic ADC surrogate, or “ADC Mimic,” with highly similar physicochemical properties to commercial ADCs provides an excellent molecule to safely drive analytical method development for ADCs.
ADC Mimic – MSQC4 plus 2, 4, 6, or 8 dansylcadaverine- SMCC mimic-linkers. Each conjugation to a Cys residue imparts a +668 Da mass shift.
Here, we build on previous work describing the preparation of such a non-toxic ADC-Mimic by utilizing the ADC-Mimic and the underlying mAb (MSQC4) to perform a comparison of chromatographic stationary phases. We also present the use of the ADCMimic to develop a workflow to characterize ADC variants by first separating them via hydrophobic interaction chromatography (HIC), collecting fractions, and subsequently analyzing the ADC variants by RP-LC-UV-MS.
Please read and download the full Article below:6 LC-UV-MS Method Development for Antibody Drug Conjugates Using a Non-Toxic ADC-Mimic
Related content from this organisation
- DRC rejects clinical trial for experimental Ebola vaccine
- Suspected counterfeit vaccines seized in Hong Kong
- Judge overrules Trump effort to advertise drug prices
- On-demand webinar: Increasing Efficiency in the Pharma Analytical Workflow through Standards and Reference Materials
- Article: Tips & tricks: sensitivity gains in LC-MS